Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. (Q50658043)

17 March 2018

title

Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. (English)

1 reference

17 March 2018

gastroesophageal reflux disease

main subject

0 references

1 reference

E C Klinkenberg-Knol

1

1 reference

17 March 2018

F Nelis

2

1 reference

17 March 2018

J Dent

3

1 reference

17 March 2018

P Snel

4

1 reference

17 March 2018

B Mitchell

5

1 reference

17 March 2018

P Prichard

6

1 reference

17 March 2018

D Lloyd

7

1 reference

17 March 2018

N Havu

8

1 reference

17 March 2018

M H Frame

9

1 reference

17 March 2018

J Romàn

10

1 reference

17 March 2018

A Walan

11

1 reference

17 March 2018

Long-Term Study Group

12

1 reference

17 March 2018

language of work or name

English

0 references

publication date

1 April 2000

1 reference

17 March 2018

published in

Gastroenterology

1 reference

17 March 2018

volume

118

1 reference

17 March 2018

issue

4

1 reference

17 March 2018

page(s)

661-669

1 reference

17 March 2018

Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Outcome 5 years after 360 degree fundoplication for gastro-oesophageal reflux disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

TECHNICAL NOTE: A SILVER METHOD FOR PARAFFIN SECTIONS OF NEURAL TISSUE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Chromogranin A, B and C immunoreactivities of mammalian endocrine cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Histopathological classification of nonantral gastric endocrine growths in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

The Sydney System: histological division

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Fundoplication: how to do it? Peri-esophageal wrapping as a therapeutic principal in gastro-esophageal reflux prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Outcome of open antireflux surgery as assessed in a Nordic multicentre prospective clinical trial. Nordic GORD-Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Nissen fundoplication for reflux esophagitis. Long-term clinical and endoscopic results in 109 of 127 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

The columnar-lined esophagus. History, terminology, and clinical issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Appropriate acid suppression for the management of gastro-oesophageal reflux disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Antral atrophy, Helicobacter pylori colonization, and gastric pH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Long-term sequelae of Helicobacter pylori gastritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970135-1

10.1016/S0016-5085(00)70135-1

7 January 2021

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

10734017

1 reference

17 March 2018